165 related articles for article (PubMed ID: 37422409)
1. Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis.
Manceñido Marcos N; Novella Arribas B; Mora Navarro G; Rodríguez Salvanés F; Loeches Belinchón P; Gisbert JP
Dig Liver Dis; 2024 Mar; 56(3):421-428. PubMed ID: 37422409
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
[TBL] [Abstract][Full Text] [Related]
3. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Nguyen NH; Solitano V; Vuyyuru SK; MacDonald JK; Syversen SW; Jørgensen KK; Crowley E; Ma C; Jairath V; Singh S
Gastroenterology; 2022 Oct; 163(4):937-949.e2. PubMed ID: 35753383
[TBL] [Abstract][Full Text] [Related]
4. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
[TBL] [Abstract][Full Text] [Related]
5. Is Therapeutic Drug Monitoring for Anti-tumour Necrosis Factor Agents in Adults With Inflammatory Bowel Disease Ready for Standard of Care? A Systematic Review and Meta-analysis.
Shah R; Hoffman GR; El-Dallal M; Goldowsky AM; Chen Y; Feuerstein JD
J Crohns Colitis; 2020 Sep; 14(8):1057-1065. PubMed ID: 32064510
[TBL] [Abstract][Full Text] [Related]
6. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW; Jørgensen KK; Goll GL; Brun MK; Sandanger Ø; Bjørlykke KH; Sexton J; Olsen IC; Gehin JE; Warren DJ; Klaasen RA; Noraberg G; Bruun TJ; Dotterud CK; Ljoså MKA; Haugen AJ; Njålla RJ; Zettel C; Ystrøm CM; Bragnes YH; Skorpe S; Thune T; Seeberg KA; Michelsen B; Blomgren IM; Strand EK; Mielnik P; Torp R; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
JAMA; 2021 Dec; 326(23):2375-2384. PubMed ID: 34932077
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease.
Sethi S; Dias S; Kumar A; Blackwell J; Brookes MJ; Segal JP
Aliment Pharmacol Ther; 2023 Jun; 57(12):1362-1374. PubMed ID: 36495020
[TBL] [Abstract][Full Text] [Related]
8. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
Papamichael K; Stocco G; Ruiz Del Agua A
Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
[TBL] [Abstract][Full Text] [Related]
9. Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review.
Schneider C; Stratman S; Choragudi S; Lev-Tov H
J Drugs Dermatol; 2023 May; 22(5):445-450. PubMed ID: 37133467
[TBL] [Abstract][Full Text] [Related]
10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
Mitrev N; Leong RW
Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
[TBL] [Abstract][Full Text] [Related]
12. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
[TBL] [Abstract][Full Text] [Related]
13. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW; Goll GL; Jørgensen KK; Sandanger Ø; Sexton J; Olsen IC; Gehin JE; Warren DJ; Brun MK; Klaasen RA; Karlsen LN; Noraberg G; Zettel C; Ljoså MKA; Haugen AJ; Njålla RJ; Bruun TJ; Seeberg KA; Michelsen B; Strand EK; Skorpe S; Blomgren IM; Bragnes YH; Dotterud CK; Thune T; Ystrøm CM; Torp R; Mielnik P; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
JAMA; 2021 May; 325(17):1744-1754. PubMed ID: 33944876
[TBL] [Abstract][Full Text] [Related]
14. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
15. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
[TBL] [Abstract][Full Text] [Related]
16. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.
Lyles JL; Mulgund AA; Bauman LE; Su W; Fei L; Chona DL; Sharma P; Etter RK; Hellmann J; Denson LA; Minar P; Dykes DM; Rosen MJ
Inflamm Bowel Dis; 2021 Mar; 27(4):482-492. PubMed ID: 32448898
[TBL] [Abstract][Full Text] [Related]
17. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
18. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
[TBL] [Abstract][Full Text] [Related]
19. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
[TBL] [Abstract][Full Text] [Related]
20. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.
Samuels A; Whaley KG; Minar P
Curr Gastroenterol Rep; 2023 Nov; 25(11):323-332. PubMed ID: 37695555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]